Food and Drug Administration Reduces Drug Study Requirement

The United States — Food and Drug Administration (United States — Food and Drug Administration) announced a significant policy change, dropping its long-standing requirement of two rigorous studies for new drug approvals to a single study. This move, championed by United States — Food and Drug Administration Commissioner Marty Makary and deputy Vinay Prasad, aims to slash bureaucracy and accelerate the availability of new medicines, potentially leading to a 'surge in drug development.' The change reflects modern scientific advances and aligns with a decades-long trend where the United States — Food and Drug Administration has increasingly accepted single studies for rare or fatal diseases, a practice supported by former United States — Food and Drug Administration drug director Janet Woodcock. However, this new approach contrasts with the United States — Food and Drug Administration's more restrictive stance on vaccines and gene therapies, as exemplified by the initial rejection and subsequent conditional review of Moderna's mRNA flu shot application by Vinay Prasad's vaccine division. This inconsistency has left the drug industry uncertain about the United States — Food and Drug Administration's overall implementation strategy.